Navidea Biopharmaceuticals Inc   (NAVB)
Other Ticker:  
Price: $0.0440 $0.01 25.714%
Day's High: $0.05 Week Perf: 28.65 %
Day's Low: $ 0.04 30 Day Perf: 10 %
Volume (M): 55 52 Wk High: $ 0.28
Volume (M$): $ 2 52 Wk Avg: $0.08
Open: $0.04 52 Wk Low: $0.02

 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 99
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision diagnostics and therapeutics for various diseases, including cancer. The company utilizes innovative technology and scientific expertise to create targeted imaging agents and therapeutic solutions that help physicians better detect, monitor, and treat diseases. Navidea's products aim to improve patient outcomes and provide healthcare professionals with valuable tools for decision-making. The company is committed to advancing healthcare through its research and development efforts.

   Company Address: 4995 Bradenton Avenue, Suite 240 Dublin 43017 OH
   Company Phone Number: 793-7500   Stock Exchange / Ticker: NAVB


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc Turns the Tide: Destroys Deficit with $0.02 Per Share Profit in Q3 2023!

Navidea Biopharmaceuticals Inc (NAVB) has recently reported its financial results for the fiscal time-frame of July to September 2023. While the company did incur losses of $-0.02 per share during this period, it is worth noting the significant improvement compared to a loss of $-0.25 per share in the same quarter last year. Furthermore, earnings per share fell from $0.12 per share in the previous quarter, indicating a slight setback.
Although the revenue remained stagnant at $0.00 million, it is important to recognize that this figure was also consistent with the previous year's comparable quarter. Additionally, the revenue remained unchanged sequentially, indicating stability in the company's financial performance.

Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc Delivers Strong Financial Results in Q2 2023 with Surge in Profits and Increase in Inventories

Navidea Biopharmaceuticals Inc, a leading biopharmaceutical company, recorded positive financial results for the second quarter of 2023. The company achieved profitability with a significant increase in Income per Share compared to the previous year. Additionally, Navidea Biopharmaceuticals Inc experienced a notable surge in net profits and a rise in inventories. Let's analyze these financial results in detail and put them into context.
Financial Performance in Q2 2023:
Navidea Biopharmaceuticals Inc demonstrated a strong improvement in its financial performance during the second quarter of 2023. The company reported an Income per Share of $0.12, a significant improvement from the negative $0.10 reported in the same period a year ago. Moreover, the EPS turned positive from negative $0.05 per share in the previous reporting period.

Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc Reports Significant Improvement in Q1 2023 Operating Loss, Positive Signs of Efficiency and Growth

As the earnings cycle for the first quarter of fiscal year 2023 continues, Navidea Biopharmaceuticals Inc announced their operating loss for the months of January to March 31, 2023. The emerging growth business disclosed a loss of $-2.422369 million, which is a significant improvement compared to the first quarter of the previous year. In the same period in 2022, the company suffered an operating loss of $-2.979284 million.
Although the business is still incurring losses, the good news is that there has been a considerable improvement in the figures, which is a sign that the company is moving towards greater efficiency. Returns for Navidea Biopharmaceuticals have also shown improvement. The company reported a diminishing return of $-1.476 million in the first quarter of 2023, a significant improvement when compared to $-2.987 million in the same period in 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com